Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan How

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Blood Advances|September 18, 2024
Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosisRathnam K Venkat, Robert A Redd, Amyah C Harris, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Leukemia|February 26, 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicingJonas S Jutzi, Edie Crosse, Chulwoo J Kim, et al.
Leukemia|February 24, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasmsBenjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2021
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort StudyVivek Naranbhai, Claire A Pernat, Alexander Gavralidis, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Blood Advances|September 18, 2024
Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosisRathnam K Venkat, Robert A Redd, Amyah C Harris, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Leukemia|February 26, 2026
Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicingJonas S Jutzi, Edie Crosse, Chulwoo J Kim, et al.
Leukemia|February 24, 2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasmsBenjamin Rolles, Cilomar Martins de Oliveira Filho, Nathan Fergusson, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2021
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort StudyVivek Naranbhai, Claire A Pernat, Alexander Gavralidis, et al.
Pageof 5